Crispr Therapeutics Email Format

Biotechnology Research
201-500 employees
Boston, MA, USA

Crispr Therapeutics is a biotechnology company pioneering CRISPR-based gene editing therapies for hemoglobinopathies, oncology, cardiovascular, and rare diseases worldwide.

Find contacts at Crispr Therapeutics

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@crisprtx.com

Company Overview

Industry
Biotechnology Research
Founded
2013
Headquarters
Boston, MA, USA
Revenue
$25M-$50M
FUNDING Stage
Public
Key Executives
Samarth Kulkarni (Chief Executive Officer and Chairman of the Board), Raju Prasad, Ph.D. (Chief Financial Officer), Stephen Kennedy (Head of Technical Operations)

Tech Stack

Okta

Security

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Crispr Therapeutics?

Crispr Therapeutics uses the first.last format on crisprtx.com, so Jane Smith would be jane.smith@crisprtx.com.

What approved therapy has Crispr Therapeutics brought to market for sickle cell disease?

Crispr Therapeutics, in collaboration with Vertex Pharmaceuticals, developed CASGEVY (exagamglogene autotemcel), which received FDA approval in December 2023 as the world's first CRISPR/Cas9-based gene therapy for sickle cell disease and transfusion-dependent beta thalassemia.

Who is the CEO of Crispr Therapeutics?

Samarth Kulkarni serves as Chief Executive Officer and Chairman of the Board at Crispr Therapeutics. You can use Clay to find and verify his current contact information if you are building outreach for the company.

Does Crispr Therapeutics have programs in cardiovascular disease beyond hemoglobinopathies?

Yes, Crispr Therapeutics has multiple in vivo cardiovascular programs in its pipeline, including CTX310 targeting ANGPTL3, CTX320 targeting Lp(a), and CTX340 targeting AGT for refractory hypertension, all using lipid nanoparticle delivery to the liver.

How many people work at Crispr Therapeutics and where is the company headquartered?

Crispr Therapeutics employs approximately 359 people and is headquartered in Boston, MA. If you need to reach specific contacts there, tools like Clay can help you find and verify individual email addresses using the first.last@crisprtx.com format.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles